Review article: Natural history and prognostic prediction of patients with hepatocellular carcinoma

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 17, Issue 2, 2003, Pages 98-102

  Varela, M ^a   Sala, M ^a   Llovet, J M ^a   Bruix, J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL PRACTICE; CONFERENCE PAPER; EVALUATION; HISTORY OF MEDICINE; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER TRANSPLANTATION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; TREATMENT INDICATION;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; NEOPLASM STAGING; PROGNOSIS;

EID: 0038574308     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (39)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden. Globocan 2000. Int J Cancer 2001; 94(2): 153-6.
2. Bruix J, Sherman M, Llovet JM, et al. Clinical Management of Hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001; 35: 421-30.
3. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in HCC. Hepatology 2002; 35(3): 519-24.
4. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19(3): 329-38.
5. Ebara M, Hatano R, Fukuda H, Yoshikawa M, Sugiura N, Saisho H. Natural course of small hepatocellular carcinoma with underlying cirrhosis. A study of 30 patients. Hepatogastroenterology 1997; 45(Suppl. 3): 1214-20.
6. Barbara L, Benzi G, Gaiani S, et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology 1992; 16(1): 132-7.
7. Livraghi T, Bolondi L, Buscarini L, et al. No treatment. resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. Italian Cooperative HCC Study Group. J Hepatol 1995; 22(5): 522-6.
8. Llovet JM, Fuster J, Bruix J. Intention-to-Treat Analysis of Surgical Treatment for Early Hepatocellular Carcinoma. Resection Versus Transplantation. Hepatol 1999; 30(6): 1434-40.
9. Bismuth H, Majno PE. Hepatobiliary surgery, J Hepatol 2000; 32(1 Suppl.): 208-24.
10. Livraghi T, Giorgio A, Marin G, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 1995; 197(1); 101-8.
11. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334(11): 693-9.
12. Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. Hepatology 2000; 32(6): 1224-9.
13. Izumi R, Shimizu K, Li T, et al. Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterol 1994; 106(3): 720-7.
14. Okada S, Shimada K, Yamamoto J, et al. Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterol 1994; 106(6): 1618-24.
15. Llovet JM, Bruix J, Fuster J, et al. Liver transplantation for treatment of small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. Hepatology 1998; 27(6): 1572-7.
16. Jonas S, Bechstein WO, Steinmuller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33(5): 1080-6.
17. Yao FY, Bass NM, Nikolai B, et al. Liver transplantation for hepatocellular carcinoma: Analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 2002; 8(10): 873-83.
18. Shiina S, Tagawa K, Niwa Y, et al. Percutaneous ethanol injection therapy for hepatocellular carcinoma: results in 146 patients. Am J Roentgenol 1993; 160(5): 1023-8.
19. Lencioni R, Pinto F, Armillotta N, et al. Long-term results of percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: a European experience. Eur Radiol 1997; 7(4): 514-9.
20. Vilana R, Bruix J, Bru C, Ayuso C, Sole M, Rodes J. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology 1992; 16(2): 353-7.
21. Ishii H, Okada S, Nose H, et al. Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection. Cancer 1996; 77(9); 1792-6.
22. Primack A, Vogel CL, Kyalwazi SK, Ziegler JL, Simon R, Anthony PP. A staging system for hepatocellular carcinoma: prognostic factors in Ugandan patients. Cancer 1975; 35(5): 1357-64.
23. Chlebowski RT, Tong M, Weissman J, et al. Hepatocellular carcinoma. Diagnostic and prognostic features in North American patients. Cancer 1984; 53(12): 2701-6.
24. Attali P, Prod'homme S, Pelletier G, et al. Prognostic factors in patients with hepatocellular carcinoma. Attempts for the selection of patients with prolonged survival. Cancer 1987; 59(12): 2108-11.
25. Falkson G, Cnaan A, Schutt AJ, Ryan LM, Falkson HC. Prognostic factors for survival in hepatocellular carcinoma. Cancer Res 1988; 48(24 Part 1): 7314-8.
26. Calvet X, Bruix J, Gines P, et al. Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients. Hepatology 1990; 12(4 Part 1): 753-60.
27. Stuart KE, Anand AJ. Jenkins RL. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome and survival, Cancer 1996; 77(11): 2217-22.
28. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma. Diagnosis treatment. Gastroenterol 2002; 122(6): 1609-19.
29. Castells A, Bruix J, Bru C, et al. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterol 1995; 109(3): 917-22.
30. Bruix J, Llovet JM, Castells A, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27(6): 1578-83.
31. Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29(1): 62-7.
32. Sorensen JB, Klee M, Palshof T, Hansen HH. Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer 1993; 67(4): 773-5.
33. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 Patients. Cancer 1985; 56(4): 918-28.
34. The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma, a retrospective study of 435 patients. Hepatology 1998; 28(3): 751-5.
35. Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. J Hepatol 1999; 31(1): 133-41.
36. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60(8); 646-9.
37. Anon, In: Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M, eds. AJCC Cancer Staging Handbook 2002.
38. Villa E, Moles A, Ferretti I, et al. Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival. Hepatology 2000; 32(2): 233-8.
39. Llovet JM, Real MI, Montanya X, et al. Arterial embolization, chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. The Lancet 2002; 359: 1734-41.